Sep 18, 2020 / 12:30PM GMT
Operator
Greetings. Welcome to Alkermes ESMO Data Conference Call. My name is Rob and I'll be your operator for today's call. (Operator Instructions) Please note, this conference is being recorded.
I will now turn the call over to Sandra Coombs, Vice President of Investor Relations. Sandy, you may begin.
Sandra Coombs - Alkermes plc - Co-Head of IR
Thank you, and welcome to the Alkermes plc conference call and webcast to discuss new clinical data and updates from our ongoing ARTISTRY-1 clinical trial of ALKS 4230, our investigational agent in oncology. These data are being presented as a mini oral presentation at the European Society for Medical Oncology 2020 Virtual Meeting.
Please note that during today's call, we will reference slides that are available on the webcast. If you have not done so already, please go to the Investors section of our website, alkermes.com, to access the webcast player. A PDF of the slides will be made available on our website following the conclusion of this call.
During this presentation, we will be making
Alkermes Plc Investor Event at the 2020 European Society for Medical Oncology Virtual Congress Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot